Braeburn is developing long-acting medicines for treating opioid addiction.
Opioid addiction is a medical condition requiring medical treatment. Together with counseling and support, Braeburn’s next generation medicines allow patients to focus on the reintegration of their lives and communities. Braeburn’s products are positioned to provide a key solution in treating OUD (opioid use disorder). Braeburn’s long-acting formulations are intended to be administered by the healthcare professional. Administration by healthcare professionals ensures delivery and medication adherence while potentially minimizing risks of diversion, misuse, and accidental pediatric exposure.
Leadership
Mike Derkacz
President & CEO
David J. McIntyre
EVP, CFO, & Treasurer
Sonnie Kim, Pharm.D.
Chief Scientific Officer
Paul Johnson
Chief Commercial Officer
Susan Franks, MS
SVP & Head of Regulatory Affairs
Ted Buckley, PhD
VP, Government Affairs
PIPELINE
Braeburn develops next generation pharmaceuticals for opioid addiction treatment.
The focus of Braeburn is primarily on opioid dependence but it is also our aim to address other therapeutic areas in pain where our competence and technologies can create value.
CAM2038
Our product pipeline targets opioid use disorder, with CAM2038 weekly and CAM2038 monthly formulations. CAM2038 is an investigational extended-release buprenorphine injection for subcutaneous administration. CAM2038’s proprietary FluidCrystal® delivery system enables a gel-like encapsulation of buprenorphine under the skin which allows for release over a period of a week or a month.
NEWS
CONTACT
ADDRESS
Braeburn
450 Plymouth Rd, Suite 400
Plymouth Meeting, PA 19462
General inquiries
610-467-8680
info@braeburnrx.com
INVESTOR RELATIONS
Chris Taylor
ctaylor@braeburnrx.com
MEDIA RELATIONS
Colleen Saltmer
csaltmer@braeburnrx.com
ADVERSE EVENT
To report SUSPECTED ADVERSE REACTIONS, contact Braeburn at 1-844-859-6341 or
FDA at 1-800-FDA-1088 or www.fda.gov/medwatch